Literature DB >> 15855531

Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

Joanne E Tomassini1, Krista Getty, Mark W Stahlhut, Sung Shim, Balkrishen Bhat, Anne B Eldrup, Thazha P Prakash, Steven S Carroll, Osvaldo Flores, Malcolm MacCoss, Daniel R McMasters, Giovanni Migliaccio, David B Olsen.   

Abstract

Nucleosides have been widely used in the treatment of viral diseases, but relatively few have been identified as inhibitors of hepatitis C virus (HCV). The modified ribonucleosides, 2'-C-methyl-adenosine and 2'-O-methyl-cytidine, are potent inhibitors of HCV replication which specifically target the NS5B polymerase. Herein, a more extensive characterization of the effect of these compounds upon HCV replication in subgenomic replicons is reported. A highly selective antireplicative effect induced by the nucleosides in replicon-containing cell lines was maintained during an exponential growth period with potencies which paralleled the reduction of both positive- and negative-strand RNA replication. Moreover, the inhibitory effect closely correlated with the intrinsic metabolic properties of differing replicon clonal lines. Interestingly, while 2'-C-methyl-adenosine elicited similar inhibitory potencies in different cell lines, 2'-O-methyl-cytidine was found to be inactive in one replicon cell line tested, although the corresponding triphosphates comparably inhibited the in vitro activity of replication complexes isolated from these cells and the activity of NS5B polymerase using synthetic templates. The lack of antireplicative effect, attributed to poor intracellular conversion of the 2'-O-methyl-cytidine nucleoside to the active 5'-triphosphate, was reversed using a monophosphate prodrug. Thus, although replicon cells are useful for evaluating the effect of inhibitors upon HCV replication, these findings have important implications for their use in the identification and characterization of nucleosides and other chemotherapeutic agents requiring cellular metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855531      PMCID: PMC1087620          DOI: 10.1128/AAC.49.5.2050-2058.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays.

Authors:  S S Carroll; V Sardana; Z Yang; A R Jacobs; C Mizenko; D Hall; L Hill; J Zugay-Murphy; L C Kuo
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

2.  Antiviral drugs: current state of the art.

Authors:  E De Clercq
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

Review 3.  Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

Authors:  D S Stein; K H Moore
Journal:  Pharmacotherapy       Date:  2001-01       Impact factor: 4.705

4.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?

Authors:  Frank Narjes; Uwe Koch; Christian Steinkühler
Journal:  Expert Opin Investig Drugs       Date:  2003-02       Impact factor: 6.206

7.  Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.

Authors:  Thazha P Prakash; Marija Prhavc; Anne B Eldrup; P Dan Cook; Steven S Carroll; David B Olsen; Mark W Stahlhut; Joanne E Tomassini; Malcolm MacCoss; Sheila M Galloway; Catherine Hilliard; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

8.  Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition.

Authors:  Meitian Wang; Kenneth K-S Ng; Maia M Cherney; Laval Chan; Constantin G Yannopoulos; Jean Bedard; Nicolas Morin; Nghe Nguyen-Ba; Moulay H Alaoui-Ismaili; Richard C Bethell; Michael N G James
Journal:  J Biol Chem       Date:  2002-12-30       Impact factor: 5.157

9.  Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation.

Authors:  Damien O'Farrell; Rachel Trowbridge; David Rowlands; Joachim Jäger
Journal:  J Mol Biol       Date:  2003-02-28       Impact factor: 5.469

10.  Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons.

Authors:  Giovanna Mottola; Giorgia Cardinali; Alessandra Ceccacci; Caterina Trozzi; Linda Bartholomew; Maria Rosaria Torrisi; Emanuela Pedrazzini; Stefano Bonatti; Giovanni Migliaccio
Journal:  Virology       Date:  2002-02-01       Impact factor: 3.616

View more
  8 in total

Review 1.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

2.  General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues.

Authors:  Hélène Dutartre; Cécile Bussetta; Joëlle Boretto; Bruno Canard
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

3.  Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line.

Authors:  Marc P Windisch; Michael Frese; Artur Kaul; Martin Trippler; Volker Lohmann; Ralf Bartenschlager
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

Authors:  Amy Fung; Zhinan Jin; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

5.  Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.

Authors:  Jamie J Arnold; Suresh D Sharma; Joy Y Feng; Adrian S Ray; Eric D Smidansky; Maria L Kireeva; Aesop Cho; Jason Perry; Jennifer E Vela; Yeojin Park; Yili Xu; Yang Tian; Darius Babusis; Ona Barauskus; Blake R Peterson; Averell Gnatt; Mikhail Kashlev; Weidong Zhong; Craig E Cameron
Journal:  PLoS Pathog       Date:  2012-11-15       Impact factor: 6.823

6.  Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.

Authors:  Jérôme Deval; Megan H Powdrill; Claudia M D'Abramo; Luciano Cellai; Matthias Götte
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

Review 7.  Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES).

Authors:  Erik De Clercq
Journal:  Adv Antivir Drug Des       Date:  2007-09-02

8.  The Enzyme-Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid.

Authors:  Dejana Jovanovic; Peter Tremmel; Pradeep S Pallan; Martin Egli; Clemens Richert
Journal:  Angew Chem Int Ed Engl       Date:  2020-09-15       Impact factor: 16.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.